Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis.
Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol. 2001 May 15; 166(10):5878-81.